^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Idafang (ivonescimab)

    i
    Other names: AK112, AK 112, AK-112, SMT112, SMT-112, SMT 112
    Company:
    Akesobio, Summit Therapeutics
    Drug class:
    PD1 inhibitor, VEGF inhibitor
    Related drugs:
    1d
    A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=132, Not yet recruiting, Akeso
    New P2 trial
    |
    Idafang (ivonescimab)
    5d
    Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 overexpression • HER-2 amplification
    |
    Herceptin (trastuzumab) • trastuzumab rezetecan (SHR-A1811) • Idafang (ivonescimab)
    6d
    Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets (clinicaltrials.gov)
    P2, N=158, Not yet recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Trial completion date: Oct 2031 --> Apr 2032 | Initiation date: Apr 2026 --> Nov 2026 | Trial primary completion date: Jan 2031 --> Jan 2032
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • Idafang (ivonescimab)
    7d
    Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, Peking University People's Hospital | Active, not recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    Idafang (ivonescimab)
    7d
    A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=265, Not yet recruiting, Akeso
    New P1/2 trial
    |
    carboplatin • Idafang (ivonescimab)
    8d
    A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=16, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement
    |
    Tepmetko (tepotinib) • Idafang (ivonescimab)
    12d
    Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 in Combination With Ivonescimab in Sq-NSCLC Patients (clinicaltrials.gov)
    P1, N=13, Not yet recruiting, Everest Medicines (Beijing) Co., Ltd.
    New P1 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Idafang (ivonescimab)
    13d
    FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov)
    P2, N=716, Recruiting, Fudan University | Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • FOXC1 (Forkhead Box C1)
    |
    Herceptin (trastuzumab) • carboplatin • Focus V (anlotinib) • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • Andewei (benmelstobart) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • Idafang (ivonescimab) • bulumtatug fuvedotin (9MW2821) • AiRuiLi (adebrelimab) • IBI-354 • SHR-4602 • TQB2102 • TQB2868 • anbenitamab repodatecan (JSKN003) • tizetatug rezetecan (SHR-A1921)
    13d
    Case Report: Personalized treatment in an advanced lung adenocarcinoma patient with EGFR exon 21 L858R mutations based on the patient-derived tumor organoids. (PubMed, Front Oncol)
    Although Osimertinib was initiated as first-line therapy based on the identified EGFR exon 21 L858R mutations, the patient experienced disease progression. Subsequent treatment with ivonescimab plus pemetrexed disodium was administered, but disease progression persisted...Our case demonstrates that the lung cancer organoids serve as a powerful preclinical platform for individualized treatment selection in patients with advanced lung adenocarcinoma via rapid functional drug screening. This personalized strategy shows great potential to optimize clinical outcomes for heavily pretreated patients.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R
    |
    Tagrisso (osimertinib) • pemetrexed • Trodelvy (sacituzumab govitecan-hziy) • Idafang (ivonescimab)
    19d
    A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) (clinicaltrials.gov)
    P1/2, N=184, Not yet recruiting, GlaxoSmithKline
    New P1/2 trial • Pan tumor
    |
    CD276 (CD276 Molecule)
    |
    Idafang (ivonescimab) • risvutatug rezetecan (GSK5764227)
    19d
    Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants. (clinicaltrials.gov)
    P2, N=252, Not yet recruiting, Shanghai Allink Biotherapeutics Co., Ltd.
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    PD-L1 expression • EGFR expression • MET expression
    |
    Tagrisso (osimertinib) • carboplatin • Idafang (ivonescimab)
    21d
    ILLUMINE: Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN (clinicaltrials.gov)
    P3, N=780, Recruiting, Groupe Oncologie Radiotherapie Tete et Cou | Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2030 --> May 2030
    Enrollment open • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Idafang (ivonescimab) • ligufalimab (AK117)